| Avian Sarcoma Leukosis Virus | |
|---|---|
| Virus classification | |
| Group: | Group VI (ssRNA-RT) |
| Family: | Retroviridae |
| Subfamily: | Orthoretrovirinae |
| Genus: | Alpharetrovirus |
| Species: | Avian leucosis virus |
Avian sarcoma leukosis virus (ASLV) is an endogenous retrovirus that infects and can lead to cancer in chickens; experimentally it can infect other species of birds and mammals.[1][2] ASLV replicates in chicken embryo fibroblasts, the cells that contribute to the formation of connective tissues. Different forms of the disease exist, including lymphoblastic, erythroblastic, and osteopetrotic.
Avian Sarcoma Leukosis Virus is characterized by a wide range of tumors, the most common of which are lymphomas. The disease is also characterized by an enlarged liver due to infiltration of cancerous lymphoid cells. In addition, other abdominal organs and the bursa of Fabricius are often infected.[3]
Contents |
Sarcoma in chickens has been studied since the early 1900s when Ellerman and Bang demonstrated that erythroleukemia can be transmitted between chickens by cell-free tissue filtrates, and in 1911 when (Francis) Peyton Rous proved that sarcoma can be transmitted through cell free extracts of solid chicken tumors[4]. Rous was awarded the Nobel Prize for his discovery in 1966 [5].
By the 1960s, ASLV became a problem with egg-laying hens and effort was made to isolate the disease. However, the movement was unsuccessful in maintaining leukosis-free flocks. In 1961, Rous sarcoma virus (RSV), which is closely related to ASLV, was shown to contain RNA, and oncogenic viruses, such as RSV and ASLV, were termed RNA tumor viruses. By the late 1960s, Howard Temin hypothesized that RSV made a copy of its own DNA and integrated that into the host cell’s chromosomal DNA. Much debate in the scientific community surrounded this issue until DNA integration was demonstrated by Temin in 1968 and reverse transcriptase was independently discovered by both Temin and David Baltimore in 1970. Temin and Baltimore won the Nobel Prize in Medicine in 1975 [5].
Today, research is carried out on ASLV in order to better understand retroviral cell entry. Since ASLV uses distinct cellular receptors to gain entry into cells, it has proven useful for understanding the early events in retroviral infection [6]. A detailed understanding of retroviral cell entry may lead to the discovery of ways in which to block the viruses from entering cells. Retroviruses also have the potential to serve as gene delivery vectors in gene therapy.
ASLV is a Group VI virus of the family Retroviridae. It is of the Alpharetrovirus genus, and has a C-type morphology. Hence, it is an enveloped virus with a condensed, central core, and has barely visible envelope spikes, or proteins [4].
ASLV is divided into six subgroups, labelled A through E and J, each having a different antigenicity due to variances in viral envelope glycoproteins. Strains A through E are highly related and are believed to have evolved from the same ancestor[7]. The subgroups evolved to utilize difference cellular receptors to gain entry into avian cells due to the host developing resistance to viral entry [8]. Some antigenic variation can occur within subgroups, and all strains are oncogenic, but oncogenicity and the ability to replicate varies between subgroups [2].
Like many retroviruses, ASLV consists of a lipid envelope containing transmembrane and cell surface glycoproteins. Enclosed within the envelope is a capsid surrounding single stranded RNA, integrase, protease, and reverse transcriptase, an enzyme that allows for the reversal of genetic transcription. As with all retroviruses, the virus is transcribed from RNA to DNA, instead of DNA to RNA as in normal cellular replication.
Viral glycoprotein-receptor interactions are required to initiate membrane fusion of the virus and cell. The surface glycoproteins contain the major domains that interact with the host cell receptor while the transmembrane (TM) glycoproteins anchor the surface glycoproteins to the virus membrane. The TM glycoproteins are directly involved in the fusion of the virus and host membranes for entry. The surface glycoproteins for subgroups A-E are almost identical and include the conservation of all cysteine amino acid residues. Viral specificity is determined by five hyper variable regions, vr1, vr2, hr1, hr2, and vr3, on the surface glycoproteins. Binding specificity is determined primarily by the hr1 and hr2 regions, with the vr3 region contributing to receptor recognition but not to binding specificity of the viral glycoprotein and cellular receptor [9].
In chicken chromosomes, three autosomal loci, t-va, t-vb, and t-vc, have been identified which control cell susceptibility of the ASLV virus subgroups A, B, and C respectively. Each of these genes codes for the cellular receptors Tva, Tvb, and Tvc.[10]. Tva contains sequences related to the ligand binding region of low-density lipoprotein receptors (LDLR) [3]. The Tvb receptor is believed to be very closely related to the receptors for both ASLV D and E, so that the ASLV D and E will bind to Tvb. Tvb is a member of the tumor necrosis factor receptor (TNFR) family [5]. The Tvc receptor is closely related to mammalian butyrophilins, which are members of the immunoglobulin superfamily [11].
ASLV is genetically closely related to the Rous sarcoma virus (RSV), but unlike RSV, ASLV does not contain the src gene, which codes for a tyrosine kinase, and does not transform the fibroblasts that it infects [2]. Both RSV and ASLV contain the gag gene, which is common to most retroviruses and encodes for the capsid proteins, and the pol gene which encodes for the reverse transcriptase enzyme. ASLV and some RSVs also contain the env gene, which encodes a precursor polyprotein that assembles in the endoplasmic reticulum. The polyproteins are then transported to the Golgi apparatus, glycosylated and cleaved to produce two glycoproteins: one surface and one transmembrane [6].
|
||||||||||||||||||||||||||||||||||